PHARMACOECONOMIC STUDY OF THE INTERRUPTION OF TREATMENT WITH TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA. EXPERIENCE IN REAL CLINICAL PRACTICE

被引：0
|
作者：
Merchan, Munoz B. [1 ]
Nuevo, Lopez, I [1 ]
De Miguel, Llorente D. [1 ]
Gil, Perez A. [1 ]
Morales, Sanz M. D. [1 ]
Perez, Ortega A. [1 ]
Guillen, Garcia H. [1 ]
Mora, Argumanez M. [1 ]
Vazquez, Ramo A. [1 ]
Santos, Morales A. B. [1 ]
Golbano, Lopez N. [1 ]
Herrero, Martin S. [1 ]
Arbeteta, Juanis J. [1 ]
Subira, D. [1 ]
机构：
[1] Hosp Univ Guadalajara, Dept Hematol, Guadalajara, Spain
来源：
HAEMATOLOGICA | 2020年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO-029
引用
收藏
页码：153 / 154
页数：2
相关论文
共 50 条
  • [1] EXPERIENCE IN REAL CLINICAL PRACTICE OF SUSPENSION OF TREATMENT WITH TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN DEEP MOLECULAR RESPONSE
    Martinez-Barranco, P.
    Barcia, I
    Villalon, L.
    Garcia Roa, M.
    Ricard, P.
    Arribalzaga, K.
    Garcia Bueno, M. J.
    Perez-Fernandez, E.
    Penalver Parraga, F. J.
    HAEMATOLOGICA, 2019, 104 : 301 - 302
  • [2] Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors
    Anna Rychter
    Piotr Jerzmanowski
    Adam Hołub
    Zofia Specht-Szwoch
    Violetta Kalinowska
    Urszula Tęgowska
    Ilona Seferyńska
    Agnieszka Kołkowska-Leśniak
    Ewa Lech-Marańda
    Joanna Góra-Tybor
    Medical Oncology, 2017, 34
  • [3] Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors
    Rychter, Anna
    Jerzmanowski, Piotr
    Holub, Adam
    Specht-Szwoch, Zofia
    Kalinowska, Violetta
    Tegowska, Urszula
    Seferynska, Ilona
    Kolkowska-Lesniak, Agnieszka
    Lech-Maranda, Ewa
    Gora-Tybor, Joanna
    MEDICAL ONCOLOGY, 2017, 34 (06)
  • [4] Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice
    Richard E. Clark
    Current Hematologic Malignancy Reports, 2019, 14 : 507 - 514
  • [5] Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice
    Clark, Richard E.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (06) : 507 - 514
  • [6] TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CHRONIC MYELOID LEUKAEMIA: A SYSTEMATIC REVIEW
    Ferdinand, R.
    Mitchell, S.
    Batson, S.
    Tumur, I.
    HAEMATOLOGICA, 2012, 97 : 533 - 533
  • [7] Chronic myeloid leukaemia (CML) audit and review of clinical experience with tyrosine kinase inhibitors (TKI) (CARCET): a population based study of the management of chronic myeloid leukaemia in Leicester
    Gooding, R. C.
    Martin, A. G. M.
    Hunter, A. E.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 : 57 - 58
  • [8] Chronic myeloid leukaemia development in the course of ccRCC treatment with tyrosine kinase inhibitors
    Czarnecka, A. M.
    Oborska, S.
    Rzepecki, P.
    Szczylik, C.
    BJU INTERNATIONAL, 2013, 112 : 12 - 13
  • [9] Tyrosine kinase inhibitors impress in treatment of myeloid leukaemia
    Fricker, Janet
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2008, 69 (02) : 72 - 72
  • [10] Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium
    Devos, Timothy
    Verhoef, Gregor
    Steel, Eva
    Mazure, Dominiek
    Lewalle, Philippe
    Bron, Dominique
    Berneman, Zwi
    Benghiat, Fleur Samantha
    Mineur, Philippe
    Theunissen, Koen
    Zachee, Pierre
    Doyen, Chantal
    Put, Natalie
    Lejeune, Marie
    Van Eygen, Koen
    Havelange, Violaine
    Reusens, Michael
    Pluymers, Wim
    Peeters, Karen
    ACTA HAEMATOLOGICA, 2019, 142 (04) : 197 - 207
12345